|
gptkbp:instanceOf
|
public-private partnership
|
|
gptkbp:conclusionDate
|
February 2022
|
|
gptkbp:coordinates
|
gptkb:Gustave_Perna
gptkb:Moncef_Slaoui
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:fundedBy
|
gptkb:U.S._Department_of_Defense
gptkb:U.S._Department_of_Veterans_Affairs
gptkb:CDC
gptkb:FDA
gptkb:NIH
gptkb:U.S._Department_of_Agriculture
gptkb:U.S._Department_of_Health_and_Human_Services
gptkb:BARDA
|
|
gptkbp:goal
|
deliver 300 million doses of safe and effective vaccines by January 2021
|
|
gptkbp:headquarters
|
gptkb:Washington,_D.C.
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Operation Warp Speed
|
|
gptkbp:launchDate
|
May 15, 2020
|
|
gptkbp:launched
|
gptkb:U.S._federal_government
|
|
gptkbp:logo
|
Operation Warp Speed logo.png
|
|
gptkbp:notableAchievement
|
accelerated clinical trials for COVID-19 vaccines
enabled mass production of COVID-19 vaccines
facilitated vaccine distribution logistics
supported rapid development of mRNA vaccines
|
|
gptkbp:partner
|
gptkb:Moderna
gptkb:Pfizer
gptkb:AstraZeneca
gptkb:Johnson_&_Johnson
gptkb:Sanofi
gptkb:Novavax
|
|
gptkbp:purpose
|
accelerate COVID-19 diagnostics development
accelerate COVID-19 therapeutics development
accelerate COVID-19 vaccine development
|
|
gptkbp:status
|
concluded
|
|
gptkbp:successor
|
gptkb:HHS_Coordination_Operations_and_Response_Element_(H-CORE)
|
|
gptkbp:website
|
https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html
|
|
gptkbp:bfsParent
|
gptkb:COVID-19
gptkb:Moderna
|
|
gptkbp:bfsLayer
|
4
|